- Home
- FLNC vs BLTE Comparison
FLNC vs BLTE Comparison
Compare FLNC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- BLTE
- Stock Information
- Founded
- FLNC 2018
- BLTE 2018
- Country
- FLNC United States
- BLTE United States
- Employees
- FLNC N/A
- BLTE N/A
- Industry
- FLNC Industrial Machinery/Components
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- BLTE Health Care
- Exchange
- FLNC Nasdaq
- BLTE Nasdaq
- Market Cap
- FLNC 2.0B
- BLTE 1.8B
- IPO Year
- FLNC 2021
- BLTE 2022
- Fundamental
- Price
- FLNC $12.37
- BLTE $56.77
- Analyst Decision
- FLNC Buy
- BLTE Strong Buy
- Analyst Count
- FLNC 17
- BLTE 4
- Target Price
- FLNC $26.12
- BLTE $96.33
- AVG Volume (30 Days)
- FLNC 3.7M
- BLTE 38.4K
- Earning Date
- FLNC 02-10-2025
- BLTE 03-10-2025
- Dividend Yield
- FLNC N/A
- BLTE N/A
- EPS Growth
- FLNC N/A
- BLTE N/A
- EPS
- FLNC 0.13
- BLTE N/A
- Revenue
- FLNC $2,698,562,000.00
- BLTE N/A
- Revenue This Year
- FLNC $48.82
- BLTE N/A
- Revenue Next Year
- FLNC $26.72
- BLTE N/A
- P/E Ratio
- FLNC $91.72
- BLTE N/A
- Revenue Growth
- FLNC 21.67
- BLTE N/A
- 52 Week Low
- FLNC $12.02
- BLTE $31.01
- 52 Week High
- FLNC $26.12
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- FLNC 33.50
- BLTE 45.77
- Support Level
- FLNC $12.43
- BLTE $56.76
- Resistance Level
- FLNC $14.93
- BLTE $60.26
- Average True Range (ATR)
- FLNC 1.04
- BLTE 3.03
- MACD
- FLNC -0.13
- BLTE 0.50
- Stochastic Oscillator
- FLNC 7.35
- BLTE 59.09
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.